The collaboration follows a partnership between AbbVie and Neomorph in January 2025, focusing on the development of molecular glue degraders. The treatments are intended for use in oncology and ...

The announcement comes less than a month after AbbVie partnered with Neomorph to develop new drug candidates for multiple targets across oncology and immunology in a deal worth $1.64bn. The ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into... ByInvesting ...

Local biotech Aardvark Therapeutics made its debut on the public market this month, making it San Diego’s first life science ...

The collaboration follows a partnership between AbbVie and Neomorph in January 2025, focusing on the development of molecular glue degraders. The treatments are intended for use in oncology and ...

The latest trading session saw AbbVie (ABBV) ending at $211.48, denoting a +1.17% adjustment from its last day's close. This change outpaced the S&P 500's 1.76% loss on the day. At the same time ...

AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb. 14. That is almost 6% higher than the prior payout. The company ...